文献速递产科母胎医学

产前提供CFTR调节剂以预防囊性纤维化相关宫内器官损伤

Offering prenatal CFTR modulators to prevent cystic fibrosis-related organ damage in utero.
PubMed 文献 · Am J Obstet Gynecol MFM · 2026-11-03

该研究报道了一个中心为8名怀有囊性纤维化(CF)风险胎儿的孕妇提供产前CFTR调节剂治疗的经验。其中2名孕妇接受ETI治疗后,胎儿超声提示的肠梗阻征象改善,出生时均无胎粪性肠梗阻。决定是否产前治疗受表型变异、保险覆盖及获益风险不确定性影响。

要点

  • 产前ETI治疗在2例中使胎儿超声提示的肠梗阻征象改善且出生时无胎粪性肠梗阻。
  • 1例因保险未授权未能用药,但出生时也无胎粪性肠梗阻。
  • 产前CFTR调节剂治疗决策复杂,需综合表型、保险及不确定性风险。

核心结论

  • 产前CFTR调节剂治疗决策复杂,受表型变异、保险覆盖不一致及潜在风险获益不确定影响。
  • 本中心8例中2例接受ETI治疗,胎儿超声提示的肠梗阻征象改善且出生时无胎粪性肠梗阻。

研究设计与样本

  • 单中心病例系列,纳入8名怀有囊性纤维化风险胎儿的孕妇。
  • 提供产前CFTR调节剂治疗选项并充分咨询潜在获益与风险,收集产前、出生及围产期常规临床记录。

主要发现

  • 8名孕妇中3名意向使用ETI,仅2名能够用药,第3名因保险未授权未能获得。
  • 1例胎儿为F508del纯合变异且胎儿影像示肠梗阻加重,27周启动ETI后出生时无胎粪性肠梗阻。
  • 另1例胎儿携带Y1032C变异(临床意义不确定)和一个致病CFTR变异,ETI启动后超声示肠梗阻征象改善,出生时无胎粪性肠梗阻。
  • 希望产前ETI但保险未覆盖的孕妇,胎儿携带一个致病变异和一个G622D变异(临床意义不确定),胎儿影像提示肠梗阻但出生时无胎粪性肠梗阻,分类为CFTR相关代谢综合征/CF筛查阳性不确定诊断。
  • 其余孕妇中3名拒绝产前CFTR调节剂治疗,1名最终产前诊断阴性,另1名终止妊娠。

临床怎么用

  • 对有CF风险的胎儿,产前咨询可讨论CFTR调节剂治疗的潜在获益与风险。
  • 临床决策需考虑胎儿基因型、表型变异及保险覆盖情况。
  • 产前ETI治疗可能改善胎儿超声提示的肠梗阻征象,但需个体化评估。

局限性

  • 单中心小样本病例系列,结果外推受限。
  • 保险授权等非医学因素影响治疗可及性。
  • 产前CFTR调节剂的潜在风险与获益尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CFTR modulator therapy has drastically improved the prognosis and quality of life for those with cystic fibrosis (CF). CF complications begin to manifest in utero, including meconium ileus, and current regulatory approvals for CFTR modulator therapy does not have a pregnancy indication. Despite this, there have been several documented cases of women taking CFTR modulator therapy during pregnancy with promising results of potential CFTR correction in utero. OBJECTIVE: To report one center's experience offering CFTR modulator therapy to pregnant women for prenatal CF treatment. STUDY DESIGN: Eight pregnant women carrying a fetus at risk of having CF were presented with the option of CFTR modulator therapy during pregnancy with extensive counseling on the potential benefits and risks. Records from routine clinical care from prenatal, birth, and perinatal period were collected. RESULTS: Of the eight pregnant women, three intended to take the CFTR modulator, elexacaftor/ tezacaftor/ ivacaftor (ETI), however only two were able, as the third was unable to obtain insurance authorization. In one case, the infant was homozygous for F508del(p.Phe508del, c.1521_1523delCTT, 1653delCTT) variant with signs of worsening bowel obstruction on fetal imaging, however after ETI initiation at 27 weeks he was born without meconium ileus. In the other case of CFTR modulator therapy treatment, the infant carried a CFTR variant of varying clinical consequence, Y1032C (c.3095A>G, p.Tyr1032Cys), and one disease causing CFTR variant. After ETI initiation, ultrasound findings suggestive of bowel obstruction improved and there was no meconium ileus at birth. The family who desired prenatal ETI therapy but was unable to obtain insurance coverage, also had one disease causing variant and one of varying clinical consequence, G622D (c.1865G>A, p.Gly622Asp). Despite fetal imaging concerning for bowel obstruction this infant had no meconium ileus at birth and was classified as CFTR related metabolic syndrome/CF Screen Positive Inconclusive Diagnosis. Of the remaining pregnant women, 3 declined prenatal CFTR modulator therapy, one ultimately had negative prenatal diagnostics, and another terminated the pregnancy. CONCLUSION: Decisions to treat with prenatal CFTR modulators are complex and influenced by multiple factors including phenotype variability, inconsistent insurance coverage, and uncertain potential risks and benefits. Outcomes of these cases ranged from pregnancy termination to successful reversal of ultrasound findings suggestive of developing meconium ileus.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Saleeb C, Gore WD, Gajo MA, et al. Offering prenatal CFTR modulators to prevent cystic fibrosis-related organ damage in utero. Am J Obstet Gynecol MFM. 2026. PMID: 42977085. doi:10.1016/j.ajogmf.2026.102180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。